Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
2.530
-0.230 (-8.33%)
Feb 21, 2025, 4:00 PM EST - Market closed
Sight Sciences Employees
Sight Sciences had 214 employees as of December 31, 2023. The number of employees decreased by 36 or -14.40% compared to the previous year.
Employees
214
Change (1Y)
-36
Growth (1Y)
-14.40%
Revenue / Employee
$371,696
Profits / Employee
-$235,290
Market Cap
128.41M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 214 | -36 | -14.40% |
| Dec 31, 2022 | 250 | 38 | 17.92% |
| Dec 31, 2021 | 212 | 43 | 25.44% |
| Dec 31, 2020 | 169 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
SGHT News
- 2 days ago - Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025 - GlobeNewsWire
- 8 days ago - Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day - GlobeNewsWire
- 2 months ago - Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options - GlobeNewsWire
- 3 months ago - Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Top 3 Health Care Stocks You'll Regret Missing In November - Benzinga
- 4 months ago - Sight Sciences to Report Third Quarter Financial Results on November 7, 2024 - GlobeNewsWire
- 4 months ago - Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial - GlobeNewsWire